Skip to main content
. Author manuscript; available in PMC: 2019 Sep 1.
Published in final edited form as: Stroke. 2018 Sep;49(9):2200–2210. doi: 10.1161/STROKEAHA.118.021179

Figure 5.

Figure 5

R(+)PPX treatment decreased ROS formation and reduced the ischemic brain injury only at 6h after reperfusion, but had no effect on the cytosolic labile zinc accumulation. R(+)PPX was injected intraperitoneally 8h and 30min before MCAO, immediately after reperfusion, and 8 and 16h after reperfusion. (A) Effect of R(+)PPX on ROS formation as indicated by H2DCF-DA-stained cells. (B) Effect of R(+)PPX on zinc accumulation as indicated by NG-stained cells. Bars=20μm. (C) Effect of R(+)PPX on cerebral infarction volume, assessed by TTC-stained coronal sections. (D) Effect of R(+)PPX on neurological assessment and motor function, assessed by neurological deficit scores and foot-fault-placing test. Data are means±SD (n=5 for A&B; n=8 for C&D). *P<0.05 vs vehicle-treated MCAO group.